Literature DB >> 31926135

The role of P2Y6R in cardiovascular diseases and recent development of P2Y6R antagonists.

Mengze Zhou1, Weiwei Wang2, Yehong Li1, Qian Zhang1, Hui Ji1, Huanqiu Li3, Qinghua Hu4.   

Abstract

As a member of the P2Y receptor family with a typical 7-transmembrane structure, P2Y6 purinergic receptor (P2Y6R) belongs to the G-protein-coupled nucleotide receptor activating the phospholipase-C signaling pathway. P2Y6R is widely involved in a range of human diseases, including atherosclerosis and other cardiovascular diseases, gradually attracting attention owing to its inappropriate or excessive activation. In addition, it was reported that P2Y6R might regulate inflammatory responses by governing the maturation and secretion of proinflammatory cytokines. Hence, several P2Y6R antagonists have been subjected to evaluation as new therapeutic strategies in recent years. This review was aimed at summarizing the role of P2Y6R in the pathogenesis of cardiovascular diseases, with an insight into the recent progress on discovery of P2Y6R antagonists.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31926135     DOI: 10.1016/j.drudis.2019.12.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

1.  Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Qasim Shah; Sarah A Lewicki; Asmita Pramanik; Varun Gopinatth; Julie Pelletier; Jean Sévigny; Jamshed Iqbal; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2022-09-08       Impact factor: 2.940

2.  Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Shanu Jain; Varun Gopinatth; Ngan B Phung; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2021-04-06       Impact factor: 2.940

Review 3.  Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases.

Authors:  Shehata Anwar; Vincent Pons; Serge Rivest
Journal:  Cells       Date:  2020-07-01       Impact factor: 6.600

Review 4.  Purinergic Signaling in Controlling Macrophage and T Cell Functions During Atherosclerosis Development.

Authors:  Davide Ferrari; Andrea la Sala; Daniela Milani; Claudio Celeghini; Fabio Casciano
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.